Filtered By:
Condition: Heart Attack
Drug: Metformin
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 151 results found since Jan 2013.
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study
The aim was to assess whether the use of additional data from the Disease Management Program (DMP) diabetes mellitus type 2 to minimize the potential for residual confounding will alter the estimated risk of either myocardial infarction, ischemic stroke or heart failure in patients with type 2 diabetes using sulfonylureas compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in addition to metformin based on routine health care data.
Source: Journal of Diabetes and Its Complications - May 18, 2016 Category: Endocrinology Authors: Dirk Enders, Bianca Kollhorst, Susanne Engel, Roland Linder, Frank Verheyen, Iris Pigeot Source Type: research
Comparative risk of major cardiovascular events associated with second‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records
ConclusionsThiazolidinedione add‐on treatments to metformin were associated with lower risks for major cardiovascular disease or cardiovascular death compared to sulphonylurea combination with metformin. Lower, but non‐statistically significant, risks were also found with DPP‐4i add‐on therapies.
Source: Diabetes, Obesity and Metabolism - May 12, 2016 Category: Endocrinology Authors: Salwa S Zghebi, Douglas T Steinke, Martin K Rutter, Richard A Emsley, Darren M Ashcroft Tags: ORIGINAL ARTICLE Source Type: research
Comparative cardiovascular safety of glucagon ‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - May 1, 2016 Category: Endocrinology Authors: E. Patorno, B. M. Everett, A. B. Goldfine, R. J. Glynn, J. Liu, C. Gopalakrishnan, S. C. Kim Tags: ORIGINAL ARTICLE Source Type: research
Comparative Cardiovascular Safety of Glucagon‐Like Peptide‐1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RA versus other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to rule out large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - March 23, 2016 Category: Endocrinology Authors: Elisabetta Patorno, Brendan M. Everett, Allison B. Goldfine, Robert J. Glynn, Jun Liu, Chandrasekar Gopalakrishnan, Seoyoung C. Kim Tags: Original Article Source Type: research
Case–control study of oral glucose‐lowering drugs in combination with long‐acting insulin and the risks of incident myocardial infarction and incident stroke
ConclusionsSulfonylureas in combination with long‐acting insulin may increase the risk of MI compared with the use of insulin alone. Metformin may be an important cardiovascular disease prevention therapy for patients on insulin therapy. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - November 8, 2015 Category: Drugs & Pharmacology Authors: James S. Floyd, Kerri L. Wiggins, Mark Christiansen, Sascha Dublin, William T. Longstreth, Nicholas L. Smith, Barbara McKnight, Susan R. Heckbert, Noel S. Weiss, Bruce M. Psaty Tags: Original Report Source Type: research
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Conclusion: Compared with sulfonylureas, DPP-4 inhibitors were associated with lower risks for all-cause death, MACEs, ischemic stroke, and hypoglycemia when used as add-ons to metformin therapy.
Primary Funding Source: None.
PMID: 26457538 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - October 13, 2015 Category: Internal Medicine Authors: Ou SM, Shih CJ, Chao PW, Chu H, Kuo SC, Lee YJ, Wang SJ, Yang CY, Lin CC, Chen TJ, Tarng DC, Li SY, Chen YT Tags: Ann Intern Med Source Type: research
The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death
Conclusions The use of a DPP-4 inhibitor combination with metformin, compared with a sulfonylurea-metformin combination, was associated with decreased risks for major cardiovascular events and all-cause mortality.
Source: Canadian Journal of Diabetes - October 3, 2015 Category: Endocrinology Source Type: research
WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus.
CONCLUSIONS: Metformin may be the first therapeutic option in the diabetes mellitus type 2 with overweight or obesity, as it may prevent some vascular complications, and mortality. Metformin produces beneficial changes in glycaemia control, and moderated in weight, lipids, insulinaemia and diastolic blood pressure. Sulphonylureas, alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, insulin, and diet fail to show more benefit for glycaemia control, body weight, or lipids, than metformin.
PMID: 26421423 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 30, 2015 Category: Journals (General) Authors: Saenz A, Fernandez-Esteban I, Mataix A, Ausejo Segura M, Roqué I Figuls M, Moher D Tags: Cochrane Database Syst Rev Source Type: research
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two- to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular ri...
Source: European Heart Journal - September 7, 2015 Category: Cardiology Authors: Ferrannini, E., DeFronzo, R. A. Tags: Clinical update Source Type: research
Association of smoking and concomitant metformin use with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes
ConclusionsIn T2D patients, concurrent treatment with metformin attenuates the observed higher cardiovascular and mortality risk in ex‐ and current smokers. In addition to smoking cessation support, treatment with metformin, particularly in ex‐ and current smokers, should be encouraged.
Source: Journal of Diabetes - July 14, 2015 Category: Endocrinology Authors: Sanjoy K. Paul, Kerenaftali Klein, Azeem Majeed, Kamlesh Khunti Tags: Original Article Source Type: research
Case–control study of second‐line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke
ABSTRACT
We conducted a population‐based case–control study to assess the myocardial infarction (MI) and stroke risks associated with sulfonylureas and insulin when used in combination with metformin. Cases had type 2 diabetes and used metformin + insulin or metformin + sulfonylureas at the time of a first MI or first stroke from 1995–2010; controls used the same treatment combinations and were randomly sampled from the same population. MI and stroke diagnoses and potential confounders were validated by medical record reviews. Compared with metformin + sulfonylurea, metformin + insulin was associated ...
Source: Diabetes, Obesity and Metabolism - July 14, 2015 Category: Endocrinology Authors: James S. Floyd, Kerri L. Wiggins, Colleen M. Sitlani, James H. Flory, Sascha Dublin, Nicholas L. Smith, Susan R. Heckbert, Bruce M. Psaty Tags: Research Letter Source Type: research
The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction
Conclusion
This proof-of-concept study shows that use of metformin in patients with DM is associated with lower 30-day all-cause mortality and tendency for a lower 12-month all-cause mortality following MI without discernible improvement in LVEF.
Source: Cardiovascular Drugs and Therapy - June 12, 2015 Category: Cardiology Source Type: research
Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
ConclusionThere were no differences in overall cardiovascular risks among several add‐on second‐line oral antidiabetic agents; however, glinide plus metformin and α‐glucosidase inhibitors plus metformin combination therapies might be associated with lower risks of acute myocardial infarction.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 1, 2015 Category: Endocrinology Authors: Y.‐C. Chang, L.‐M. Chuang, J.‐W. Lin, S.‐T. Chen, M.‐S. Lai, C.‐H. Chang Tags: Research Article Source Type: research
Association of smoking and concomitant use of metformin with cardiovascular events and mortality in people newly diagnosed with type 2 diabetes
ConclusionsIn type 2 diabetes patients, concurrent treatment with metformin attenuates the observed higher cardiovascular and mortality risk in ex‐ and current smokers. In addition to smoking cessation support, treatment with metformin, particularly in ex‐ and current smokers, should be encouraged.
Source: Journal of Diabetes - April 30, 2015 Category: Endocrinology Authors: Sanjoy K. Paul, Kerenaftali Klein, Azeem Majeed, Kamlesh Khunti Tags: Original Article Source Type: research
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(R))
CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial in subjects with early type 2 diabetes and increased cardiovascular risk or established complications that will determine the long-term cardiovascular impact of linagliptin versus the sulphonylurea glimepiride. Eligible patients were sulphonylurea-naïve with HbA1c 6.5%–8.5% or previously exposed to sulphonylurea (in monotherapy or in a combination regimen <5 years) with HbA1c 6.5%–7.5%. Primary outcome is time to first occurrence of cardiovascular death, non-fatal myocardial in...
Source: Diabetes and Vascular Disease Research - April 7, 2015 Category: Endocrinology Authors: Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., Patel, S., Johansen, O. E., Woerle, H.-J. Tags: Clinical Trial Design Source Type: research
